Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Key takeaways Regulatory Status: As of April 2026, BPC-157 is classified as a Category 2 bulk drug substance by the FDA prohibited in compounding under Section 503A and 503B
The metabolic profiling revealed that AOD9604 undergoes rapid proteolytic degradation in serum, generating a series of predictable fragment peptides
Two separate human clinical trials have investigated this compound: Ulcerative Colitis Trial Clinical investigation of this compound in patients with ulcerative colitis examined the compounds GI-protective properties properties that are consistent with its gastric origin and documented activity on intestinal permeability barriers in animal models
H.-S., & Pang, J.-H
In cases of documented vitamin deficiency, the regimen could be an initial intensive phase (like 2 mL IM three times a week for 2 weeks) followed by reevaluation
